Cargando…
Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highli...
Autores principales: | Bunnell, Kristen L., Danziger, Larry H., Johnson, Stuart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472230/ https://www.ncbi.nlm.nih.gov/pubmed/28638841 http://dx.doi.org/10.1093/ofid/ofx078 |
Ejemplares similares
-
Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile
por: Guinta, Margaret M., et al.
Publicado: (2017) -
Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013) -
Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
por: Soriano, Melinda M., et al.
Publicado: (2014) -
Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017) -
Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)